An Outbred Guinea Pig Disease Model for Lassa Fever Using a Host-Adapted Clade III Nigerian Lassa Virus.
Lassa virus
disease modelling
infectious diseases
medical countermeasures
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
17 03 2023
17 03 2023
Historique:
received:
14
02
2023
revised:
11
03
2023
accepted:
12
03
2023
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
Nigeria experiences annual outbreaks of Lassa fever (LF) with high case numbers. At least three clades of Lassa virus (LASV) have been documented in Nigeria, though recent outbreaks are most often associated with clade II or clade III viruses. Using a recently isolated clade III LASV from a case of LF in Nigeria in 2018, we developed and characterized a guinea pig adapted virus capable of causing lethal disease in commercially available Hartley guinea pigs. Uniform lethality was observed after four passages of the virus and was associated with only two dominant genomic changes. The adapted virus was highly virulent with a median lethal dose of 10 median tissue culture infectious doses. Disease was characterized by several hallmarks of LF in similar models including high fever, thrombocytopenia, coagulation disorders, and increased inflammatory immune mediators. High viral loads were noted in all solid organ specimens analyzed. Histological abnormalities were most striking in the lungs and livers of terminal animals and included interstitial inflammation, edema, and steatosis. Overall, this model represents a convenient small animal model for a clade III Nigeria LASV with which evaluation of specific prophylactic vaccines and medical countermeasures can be conducted.
Identifiants
pubmed: 36992478
pii: v15030769
doi: 10.3390/v15030769
pmc: PMC10052409
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Viral Vaccines
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS Negl Trop Dis. 2021 Mar 8;15(3):e0009169
pubmed: 33684118
Antiviral Res. 2014 Dec;112:59-79
pubmed: 25448088
Curr Top Microbiol Immunol. 2021 Apr 17;:
pubmed: 33861373
Emerg Infect Dis. 2022 Aug;28(8):1559-1568
pubmed: 35876478
Lancet Infect Dis. 2018 Jun;18(6):684-695
pubmed: 29523497
BMJ. 1995 Sep 30;311(7009):857-9
pubmed: 7580496
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736
pubmed: 25884628
J Infect Dis. 2013 Apr 15;207(8):1316-27
pubmed: 23303805
Infect Dis Poverty. 2018 Apr 28;7(1):37
pubmed: 29703243
J Infect Dis. 1987 Mar;155(3):437-44
pubmed: 3805771
Pathogens. 2020 Mar 06;9(3):
pubmed: 32155851
Am J Trop Med Hyg. 1970 Jul;19(4):670-6
pubmed: 4246571
Sci Rep. 2015 Oct 12;5:14775
pubmed: 26456301
Trans R Soc Trop Med Hyg. 2020 May 7;114(5):385-396
pubmed: 32125412
Pan Afr Med J. 2019 Oct 06;34:76
pubmed: 31819792
J Vector Borne Dis. 2007 Mar;44(1):1-11
pubmed: 17378212
Curr Opin Virol. 2019 Aug;37:vii-ix
pubmed: 31564289
Front Public Health. 2019 Jun 25;7:170
pubmed: 31294014
Zoonoses Public Health. 2012 Sep;59 Suppl 2:43-7
pubmed: 22958249
Antiviral Res. 2008 Apr;78(1):79-90
pubmed: 18036672
PLoS Pathog. 2021 Oct 11;17(10):e1009966
pubmed: 34634087
Emerg Infect Dis. 2019 Jun;25(6):1066-1074
pubmed: 31107222
Curr Opin Virol. 2019 Aug;37:77-83
pubmed: 31323506
Science. 1974 Jul 19;185(4147):263-5
pubmed: 4833828